Powerful New Treatment for the Pain of Osteoarthritis

CINGAL® is the first and only approved* combination viscosupplement that combines the proven benefits of a proprietary hyaluronic acid with a well-established steroid to provide fast acting and long lasting pain relief from osteoarthritis.

Why Cingal?

About Osteoarthritis

Osteoarthritis (OA) is a common, chronic, progressive disease that slowly deteriorates the joint. It is characterized by the loss of cartilage and a reduction in the amount of natural hyaluronic acid (HA) normally found in a healthy joint.

Learn More

Is CINGAL®  Right for You?

Only CINGAL works by combining a fast acting steroid with a long lasting viscosupplement to deliver rapid pain relief proven to last through six months.1

Current treatments

Unique New Combination Treatment

First and only approved* combination hyaluronic acid (HA) plus steroid treatment for the pain of osteoarthritis

fast acting pain relief

Steroid provides rapid short-term pain relief within days of injection1

long lasting pain relief

HA viscosupplement provides long lasting pain relief through 6 months1

convenient single-injection treatment

Simple one injection procedure that can be done in the convenience of a physician’s office

Natural Solution

Highly concentrated, non-animal based HA produced from bacterial fermentation

Safe and Effective

Strong safety profile in both an initial injection1 as well as a repeat injection2

Clinically Proven

Unprecedented rapid and long lasting knee pain relief demonstrated in the CINGAL clinical study1

CINGAL® delivers fast acting and long lasting relief from the pain of osteoarthritis. CINGAL is helping patients all over the world to once again enjoy daily physical activities with reduced pain.

The Patient Experience

Fast Acting. Long Lasting.

CINGAL IS CLINICALLY PROVEN TO DELIVER STATISTICALLY SIGNIFICANT KNEE PAIN RELIEF, PROVIDING FASTER PAIN RELIEF COMPARED TO HA ALONE, AND DEMONSTRATING SUPERIOR LONG LASTING PAIN RELIEF COMPARED TO SALINE (CONTROL).1

CLINICAL OVERVIEW


*CINGAL is CE Mark approved and Health Canada approved.

1. CINGAL 13-01, a randomized, double-blind, placebo-controlled, active comparator Phase III study. Anika Therapeutics, Inc.: study sponsor, Dr. Laszlo Hangody: global principal investigator, SynteractHCR: CRO.

2. CINGAL 13-02, an open-label, follow-on study to Cingal 13-01. Anika Therapeutics, Inc.: study sponsor, Dr. Laszlo Hangody: global principal investigator, SynteractHCR: CRO.

Access to the information in these pages is for healthcare professionals only. By clicking OK, I authorize that I am a healthcare professional.

OK